Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Lorazepam and diazepam equivalent in head-to-head study of paediatric status epilepticus

Lorazepam and diazepam have equivalent efficacy and safety for the treatment of paediatric status epilepticus, results of a randomised controlled trial suggest.

Child asleep in hospital

Source: (Monkey Business Images/

The likelihood of sedation was greater with lorazepam than diazepam

The research, which appears in a neurology themed issue of JAMA (2014;311:1652), found that intravenous formulations of the drugs were associated with similar rates of seizure control and severe respiratory depression in children presenting to emergency departments with convulsive status epilepticus.

In the UK, lorazepam or midazolam are recommended for use in children experiencing seizures whereas the US Food and Drug Administration has approved diazepam but not lorazepam. This study, by James Chamberlain, from the Children’s National Medical Centre in Washington, US, and colleagues, was undertaken in view of recent reports that lorazepam may have safety or efficacy advantages over diazepam.


The study included 273 children aged between three months and 18 years presenting to 11 paediatric hospitals in the US with generalised tonic-clonic status epilepticus. They were randomly assigned to receive either diazepam 0.2mg/kg or lorazepam 0.1 mg/kg; if convulsions continued, half this dose was given at five minutes followed by fosphenytoin at 12 minutes.

The primary efficacy outcome was cessation of status epilepticus within 10 minutes of treatment without recurrence for at least 30 minutes. This was achieved by 72.1 per cent of children in the diazepam group and 72.9 per cent of those in the lorazepam group.

The major safety outcome was the need for assisted ventilation; this was met by 16.0 per cent and 17.6 per cent of patients given diazepam and lorazapam, respectively.

The primary outcomes and all but one of the secondary outcomes did not differ significantly between the two groups. The only treatment-related difference was the likelihood of sedation, which was greater with lorazepam than with diazepam (66.9 versus 50.0 per cent).

Dr Chamberlain and co-authors conclude that “diazepam, lorazepam, or midazolam could be chosen as a reasonable first-line therapy” and add: “Future trials should consider newer medications and novel interventions targeting those at highest risk for medication failure or respiratory depression.”

Citation: The Pharmaceutical JournalURI: 11137731

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Supplementary images

  • Child asleep in hospital

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free newsletters.